Marti Technologies, Inc. ("Marti") (NYSE American: MRT), Türkiye’s leading mobility super app, will announce its financial ...
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback